SEC filing · 8-K

Sagimet Biosciences Inc.: Material agreement

Sagimet Biosciences agreed to raise approximately $107.5 million in net proceeds through an underwritten offering of common stock and pre-funded warrants.

Filed October 1, 2026

Positive for the company

What happened

On September 30, 2026, Sagimet Biosciences entered into an underwriting agreement to sell 8,750,010 shares of common stock and pre-funded warrants to purchase up to 2,750,010 shares.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Sagimet Biosciences Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.